Biocon Biologics gets 6 USFDA observations for Malaysia facility

Published On 2021-09-27 08:40 GMT   |   Update On 2022-12-14 09:21 GMT

Bangalore: Pharma major Biocon has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with 6 observations at its Malaysian subsidiary Biocon Sdn. Bhd's manufacturing facility.

The USFDA has conducted an on-site pre-approval inspection (PAI) at the company's Malaysian subsidiary Biocon Sdn. Bhd's manufacturing facility for Insulin Aspart between Sep 13 and Sep 24, 2021.

At the conclusion of the inspection, the agency has issued a Form 483 with a total of 6 observations across Drug Substance, Drug Product and Devices Facilities.

"We are confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the US FDA in the stipulated time. We do not expect the outcome of this inspection to impact our commercialization plans for insulin Aspart in the US," Biocon Spokesperson said in a statement.

"Biocon Biologics remains committed to global standards of Quality and Compliance," he further added.

Medical Dialogues team had earlier reported that Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., had received the Establishment Inspection Report (EIR) from the USFDA for the pre-approval inspection at two of its biologics manufacturing facilities in Bengaluru.

Read also: Biocon Biologics Gets USFDA EIR For Two Manufacturing Facilities

Biocon Biologics has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases.

Five molecules from Biocon Biologics' portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. 



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News